Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

F Bert

Showing results (31-40 of 112) with videos related to

Pageof 12
Sort By:
Pathologie-Biologie|May 1, 1996
[Comparison of the activity of beta-lactams against Pseudomonas aeruginosa according to phenotypes of resistance]F Bert, I Briaud, C Branger, et al.
Public Health|July 18, 2020
Health impact assessment in Italy: it is time to actF Bert, G Lo Moro, M R Gualano, et al.
BMC Research Notes|September 30, 2015
Analysis of full-text publication and publishing predictors of abstracts presented at an Italian public health meeting (2005-2007)S Castaldi, M Giacometti, W Toigo, et al.
Chemotherapy|November 1, 1996
Activities of piperacillin, ceftazidime, cefepime and cefpirome against Pseudomonas aeruginosa strains with intrinsic ticarcillin resistanceF Bert, P G Setbon, N Lambert-Zechovsky, et al.
Physical Review Letters|April 7, 2010
Ground state of the easy-axis rare-earth kagome langasite Pr3Ga5SiO14A Zorko, F Bert, P Mendels, et al.
The Journal of Infection|May 31, 2011
Physicians fail to consider Pseudomonas aeruginosa as a potential pathogen in medicine patients with bacteremiaJ Gellen-Dautremer, F Bert, X Panhard, et al.
Human Biology|May 3, 2001
Major mitochondrial DNA haplotype heterogeneity in highland and lowland Amerindian populations from BoliviaF Bert, A Corella, M Gené, et al.
Zeitschrift Fur Gastroenterologie|August 17, 2016
[Costs of a guideline-based treatment of patients with chronic hepatitis C in the era of interferon-free treatment]J T Stahmeyer, S Rossol, F Bert, et al.
Perspectives in Public Health|September 8, 2022
Outbreaks of COVID-19 in indoor places of worship: a systematic reviewF Bert, G Lo Moro, A Peano, et al.
Zeitschrift Fur Gastroenterologie|July 31, 2014
[Costs of a guideline-based treatment of patients with chronic hepatitis C in Germany]J T Stahmeyer, S Rossol, F Bert, et al.
Pageof 12

Showing results (31-40 of 112) with videos related to

Sort By:
Pageof 12
Pathologie-Biologie|May 1, 1996
[Comparison of the activity of beta-lactams against Pseudomonas aeruginosa according to phenotypes of resistance]F Bert, I Briaud, C Branger, et al.
Public Health|July 18, 2020
Health impact assessment in Italy: it is time to actF Bert, G Lo Moro, M R Gualano, et al.
BMC Research Notes|September 30, 2015
Analysis of full-text publication and publishing predictors of abstracts presented at an Italian public health meeting (2005-2007)S Castaldi, M Giacometti, W Toigo, et al.
Chemotherapy|November 1, 1996
Activities of piperacillin, ceftazidime, cefepime and cefpirome against Pseudomonas aeruginosa strains with intrinsic ticarcillin resistanceF Bert, P G Setbon, N Lambert-Zechovsky, et al.
Physical Review Letters|April 7, 2010
Ground state of the easy-axis rare-earth kagome langasite Pr3Ga5SiO14A Zorko, F Bert, P Mendels, et al.
The Journal of Infection|May 31, 2011
Physicians fail to consider Pseudomonas aeruginosa as a potential pathogen in medicine patients with bacteremiaJ Gellen-Dautremer, F Bert, X Panhard, et al.
Human Biology|May 3, 2001
Major mitochondrial DNA haplotype heterogeneity in highland and lowland Amerindian populations from BoliviaF Bert, A Corella, M Gené, et al.
Zeitschrift Fur Gastroenterologie|August 17, 2016
[Costs of a guideline-based treatment of patients with chronic hepatitis C in the era of interferon-free treatment]J T Stahmeyer, S Rossol, F Bert, et al.
Perspectives in Public Health|September 8, 2022
Outbreaks of COVID-19 in indoor places of worship: a systematic reviewF Bert, G Lo Moro, A Peano, et al.
Zeitschrift Fur Gastroenterologie|July 31, 2014
[Costs of a guideline-based treatment of patients with chronic hepatitis C in Germany]J T Stahmeyer, S Rossol, F Bert, et al.
Pageof 12